Top

World Journal of Surgery

Published in:

01-02-2020 | Metastasis | Original Scientific Report

Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies

Authors: F. M. Watzka, F. Meyer, J. I. Staubitz, C. Fottner, A. Schad, H. Lang, T. J. Musholt

Published in: World Journal of Surgery | Issue 2/2020

Abstract

Background

In contrast to exocrine pancreatic carcinomas, prognosis and treatment of pancreatic neuroendocrine neoplasms (PNEN) are significantly different. The variable growth pattern and associated clinical situation of functioning and non-functioning PNEN demand an individualized surgical approach. However, due to the scarce evidence associated with the rare disease, guidelines lack detailed recommendations for indication and for the required extent of surgical resection.

Methods

In a retrospective single-center study from 1990 to 2018, 239 patients with PNEN were identified. Clinical data were collected in the MaDoc database of the University Medical Center Mainz. A total of 155 non-functional PNEN were selected for further analysis.

Results

According to the classification of NET by the WHO in 2017, 28.8% (n = 40) of the tumors were G1, 61.9% (n = 86) G2, and 9.4% (n = 13) G3. In 73 patients, hepatic metastases were present. Sixty patients had lymph node metastasis. An R0 resection was achieved in 98 cases, an R1 situation in 10 cases. Five times, a tumor debulking was carried out (R2) and 5 times the operation was aborted without any resection because of the advanced tumor stage. A relapse occurred in 29 patients. Different prognostic factors (grade, tumor size, age) were analyzed. Grade-dependent 10-year overall survival rates were 79.5% (grade 1) and 60.1% (grade 2), respectively. The survival rate of grade 3 patients was limited to 66.7% after 13 months.

Conclusion

In our study, patients with non-functioning PNEN had a longer overall survival after successful R0 resection. The risk analysis confirmed a Ki-67 cutoff value of 5%, which divided a high- and low-risk group. Patients with a PNEC G3 (Ki-67 index > 50%) had a very poor prognosis.

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef

Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Anal Autops Cases Dig Dis Sci 36:933–942CrossRef

Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58–64CrossRef

Hallet J, Law CH, Cukier M et al (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation and outcomes. Cancer 121:589–597CrossRef

Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15:e8–21CrossRef

Fesinmeyer MD, Austin MA, Li CI et al (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14:1766–1773CrossRef

Gratian L, Pura J, Dinan M et al (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21:3515–3521CrossRef

Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRef

Rinke A, Wiedenmann B, Auernhammer C et al (2018) Practice guideline neuroendocrine tumors—AWMF-Reg. 021-27. Z Gastroenterol 56:583–681CrossRef

10.

Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw JNCCN 13:78–108CrossRef

11.

Ferrone CR, Tang LH, Tomlinson J et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25:5609–5615CrossRef

12.

Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRef

13.

Liszka L (2016) Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas. Pol J Pathol 67:318–331CrossRef

14.

Hauck L, Bitzer M, Malek N et al (2016) Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand J Gastroenterol 51:55–59CrossRef

15.

Genc CG, Jilesen AP, Partelli S et al (2018) A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg 267:1148–1154CrossRef

16.

Panzuto F, Boninsegna L, Fazio N et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29:2372–2377CrossRef

17.

Partelli S, Maurizi A, Tamburrino D et al (2014) Surgical management of pancreatic neuroendocrine neoplasms. Ann Saudi Med 34:1–5CrossRef

18.

D’Haese JG, Tosolini C, Ceyhan GO et al (2014) Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 20:13893–13898CrossRef

19.

Radu EC, Saizu AI, Grigorescu RR et al (2018) Metastatic neuroendocrine pancreatic tumor—case report. J Med Life 11:57–61PubMedPubMedCentral

20.

Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRef

21.

Watzka FM, Fottner C, Miederer M et al (2015) Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg 400:349–358CrossRef

22.

Shatveryan GA, Karagyozyan GA, Chardarov NK et al (2018) Surgical management of non-functioning pancreatic neuroendocrine tumors. Khirurgiia (Mosk). https://doi.org/10.17116/hirurgia201814-9 CrossRef

23.

Ricci C, Casadei R, Taffurelli G et al (2016) Validation of the 2010 WHO classification and a new prognostic proposal: a single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. Pancreatology 16:403–410CrossRef

24.

Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRef

Title: Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies
Authors: F. M. Watzka
F. Meyer
J. I. Staubitz
C. Fottner
A. Schad
H. Lang
T. J. Musholt
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keyword: Metastasis
Published in: World Journal of Surgery / Issue 2/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-019-05220-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Authors’ Reply: Honorary Authorships in Surgical Literature

Endocrine Surgery Without the Bells and Whistles: Editorial of the International Association of Endocrine Surgeons Symposium

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

The Role of Tumor and Lymph Node Size and Extension in Papillary Thyroid Cancer Staging

Traction Injury of Recurrent Laryngeal Nerve During Thyroidectomy

Prognostic Characteristics of Primary Squamous Cell Carcinoma of the Thyroid: A National Cancer Database Analysis